Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Status:
Completed
Trial end date:
2020-07-22
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter phase II trial designed to determine efficacy and safety
of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory
Waldenstrom's Macroglobulinemia.